Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 8:16:283-297.
doi: 10.2147/CMAR.S447546. eCollection 2024.

Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials

Winnie Yeo  1 , Nicole T Y Ngai  1 , Christopher C H Yip  1 , Frankie K F Mo  1 , Victoria A Yeo  1 , Jonathan W H Ko  1 , Leung V Li  1 , Thomas K H Lau  1 , Kwai Tung Lai  1 , Elizabeth Pang  1 , Claudia H W Yip  1 , Horatio L Yeo  1 , Carol Chi Hei Kwok  2 , Stephanie W Y Ko  1 , Alex Molassiotis  3
Affiliations

Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials

Winnie Yeo et al. Cancer Manag Res. .

Abstract

Purpose: Although risk factors related to chemotherapy-induced nausea and vomiting (CINV) have been identified in previous studies, only a few studies have evaluated the risk factors associated with contemporary antiemetic prophylaxis, including olanzapine/aprepitant- or NEPA-containing regimens. This study aimed to identify the risk factors associated with CINV development in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide chemotherapy.

Methods: Data from 304 patients enrolled in 3 previously reported prospective antiemetic studies were included. Multivariate logistic regression models were used to predict risk factors associated with CINV occurrence. Additionally, the likelihood of treatment failure in relation to the number of risk factors in individual patients was evaluated.

Results: Multivariate analysis of the entire study group revealed that obesity status (defined as body mass index/= 25.0 kg/m2) and the use of olanzapine/aprepitant- or NEPA-containing anti-emetic regimens were associated with a high likelihood, while a history of motion sickness was associated with a lower likelihood, complete response (CR), and "no nausea" in the overall phase. A history of vomiting during pregnancy was also associated with a lower likelihood of an overall CR. Patients with an increasing number of risk factors had a higher likelihood of treatment failure and shorter time to first vomiting. Those who did not achieve CR and "no nausea" in the first cycle were less likely to achieve these parameters in the subsequent cycle of chemotherapy.

Conclusion: The present study confirmed previously reported risk factors for CINV in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide. Further optimization of CINV control is required for patients with identifiable risk factors; olanzapine/aprepitant- or NEPA- containing prophylaxis are the preferred contemporary anti-emetics regimens for Chinese breast cancer patients undergoing doxorubicin and cyclophosphamide chemotherapy.

Keywords: NEPA; aprepitant; cytotoxic; nausea and vomiting; olanzapine.

PubMed Disclaimer

Conflict of interest statement

Yeo has been involved in the CINV Network in Asia and has been a speaker of the CINV organized by Mundipharma. Mundipharma supported the study design of the NEPA, but had no role in the present analysis, data collection and analysis, decision to publish, or preparation of the manuscript. Molasiotis has received grants and has been a speaker for Helsinn. Madam Diana Hon Fun Kong Donation for Cancer Research had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation. None of the other authors declare any conflict of interest. The statements presented in this paper are the sole responsibility of the authors.

Figures

Figure 1
Figure 1
Kaplan–Meier curve of time to first vomiting according to the number of identified risk factors in all patients (N=304). Purple line- no risk factors; brown line- 1 risk factor; green line- 2 risk factors; red line- 3 risk factors; blue line- 4 risk factors.
See this image and copyright information in PMC

References

    1. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2020;38:2782–2797. doi:10.1200/JCO.20.01296 - DOI - PubMed
    1. Herrstedt J, Roila F, Warr D, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25:277–288. doi:10.1007/s00520-016-3313-0 - DOI - PubMed
    1. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Antiemesis. 2023;2023:1.
    1. Yeo W, Mo FK, Suen JJ, et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009;113:529–535. doi:10.1007/s10549-008-9957-9 - DOI - PubMed
    1. Yeo W, Lau TK, Li L, et al. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. Breast. 2020;50:30–38. doi:10.1016/j.breast.2020.01.005 - DOI - PMC - PubMed

LinkOut - more resources